CEL Pocfratio vs Price To Sales Ratio Analysis
CVM Stock | USD 0.60 0.10 14.29% |
CEL SCI financial indicator trend analysis is way more than just evaluating CEL SCI Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CEL SCI Corp is a good investment. Please check the relationship between CEL SCI Pocfratio and its Price To Sales Ratio accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Pocfratio vs Price To Sales Ratio
Pocfratio vs Price To Sales Ratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CEL SCI Corp Pocfratio account and Price To Sales Ratio. At this time, the significance of the direction appears to have very week relationship.
The correlation between CEL SCI's Pocfratio and Price To Sales Ratio is 0.22. Overlapping area represents the amount of variation of Pocfratio that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of CEL SCI Corp, assuming nothing else is changed. The correlation between historical values of CEL SCI's Pocfratio and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pocfratio of CEL SCI Corp are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Pocfratio i.e., CEL SCI's Pocfratio and Price To Sales Ratio go up and down completely randomly.
Correlation Coefficient | 0.22 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Pocfratio
Price To Sales Ratio
Price to Sales Ratio is figured by comparing CEL SCI Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on CEL SCI sales, a figure that is much harder to manipulate than other CEL SCI Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Most indicators from CEL SCI's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CEL SCI Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. As of the 29th of December 2024, Enterprise Value is likely to grow to about 82.9 M, while Selling General Administrative is likely to drop about 5.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 36.1M | 31.5M | 36.2M | 38.0M | Cost Of Revenue | 3.9M | 4.0M | 3.6M | 3.1M |
CEL SCI fundamental ratios Correlations
Click cells to compare fundamentals
CEL SCI Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CEL SCI fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 40.5M | 75.9M | 50.5M | 30.5M | 35.1M | 36.9M | |
Other Current Liab | 102.2K | 863.9K | (417.5K) | 1.6M | 1.8M | 1.8M | |
Total Current Liabilities | 4.3M | 3.9M | 4.7M | 5.6M | 6.4M | 3.6M | |
Total Stockholder Equity | 19.7M | 56.5M | 32.2M | 13.2M | 15.2M | 8.4M | |
Property Plant And Equipment Net | 20.9M | 28.4M | 24.7M | 21.0M | 24.2M | 25.4M | |
Net Debt | (1.6M) | (20.1M) | (7.4M) | 9.4M | 8.5M | 8.9M | |
Retained Earnings | (381.8M) | (418.2M) | (454.9M) | (487.1M) | (438.4M) | (416.5M) | |
Cash | 15.5M | 36.1M | 22.7M | 4.1M | 4.8M | 7.7M | |
Non Current Assets Total | 22.8M | 30.6M | 25.1M | 23.6M | 27.2M | 28.5M | |
Cash And Short Term Investments | 15.5M | 42.2M | 22.7M | 4.1M | 4.8M | 8.1M | |
Common Stock Shares Outstanding | 36.8M | 40.7M | 43.1M | 44.5M | 51.2M | 53.7M | |
Liabilities And Stockholders Equity | 40.5M | 75.9M | 50.5M | 30.5M | 35.1M | 36.9M | |
Other Current Assets | 1.3M | 998.5K | 762.1K | 524.6K | 472.2K | 448.5K | |
Other Stockholder Equity | 401.2M | 474.3M | 486.6M | 499.8M | 574.8M | 603.5M | |
Total Liab | 20.8M | 19.3M | 18.4M | 17.3M | 19.9M | 20.9M | |
Property Plant And Equipment Gross | 5.8M | 32.5M | 30.6M | 29.0M | 33.3M | 35.0M | |
Total Current Assets | 17.7M | 45.3M | 25.4M | 6.9M | 8.0M | 9.9M | |
Non Current Liabilities Total | 16.5M | 15.4M | 13.7M | 11.7M | 13.5M | 14.2M | |
Short Long Term Debt Total | 13.9M | 16.0M | 15.3M | 13.6M | 15.6M | 16.4M | |
Short Term Debt | 2.1M | 1.4M | 3.5M | 2.0M | 2.3M | 1.2M | |
Intangible Assets | 313.4K | 275.9K | 212.2K | 197.7K | 177.9K | 284.1K | |
Accounts Payable | 2.0M | 1.7M | 1.6M | 2.0M | 2.3M | 1.4M | |
Net Receivables | 118.7K | 62.8K | 54.9K | (2.0M) | (1.8M) | (1.7M) | |
Common Stock Total Equity | 352.3K | 387.3K | 432.1K | 434.5K | 499.7K | 959.4K | |
Common Stock | 387.3K | 432.1K | 434.5K | 474.2K | 426.8K | 682.4K | |
Other Liab | 7.0M | 6.0M | 3.7M | 125K | 143.8K | 136.6K | |
Property Plant Equipment | 15.8M | 5.8M | 13.7M | 12.1M | 13.9M | 14.6M | |
Inventory | 820.1K | 2.0M | 2.0M | 2.2M | 2.6M | 2.7M | |
Net Tangible Assets | 5.1M | 19.4M | 56.3M | 32.0M | 36.7M | 38.6M | |
Retained Earnings Total Equity | (353.7M) | (381.8M) | (418.2M) | (454.9M) | (409.4M) | (429.9M) | |
Capital Surpluse | 358.5M | 401.2M | 474.3M | 486.6M | 559.6M | 351.9M | |
Non Current Liabilities Other | 13.5M | 13.0M | 125K | 13.7M | 143.8K | 136.6K | |
Long Term Debt Total | 13.5M | 11.8M | 13.3M | 11.7M | 13.5M | 12.5M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.63) | Return On Assets (0.61) | Return On Equity (2.50) |
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.